CD34 and essential thrombocythemia: Our findings using the in vivo CRISPR model led us to investigate whether CD34+ HSPCs derived from PV and ET patients with JAK2V617F mutation could engraft in 3D scaffolds containing MSCs from PV and ET patients, respectively.